For Sale, Buyer Sought: Teva Confirms API Unit Is On The Block
‘Pretty Neutral With Regards To Margins,’ Teva Says; H1 2025 Deadline Forecast
Teva had told investors last year that it believed it was stymying its API unit’s growth by not allowing it to stand taller on its own two feet. Now the Israeli firm has confirmed that the business, TAPI, is up for sale.